https://www.selleckchem.com/pr....oducts/bay-11-7082-b
CHMs is a potential method in the treatment of CKD. Further study on the mechanism and well-conducted RCTs are urgently needed to evaluate the efficacy and safety of CHMs.Background and Objective Tau-specific positron emission topography (PET) imaging enables in vivo assessment of Alzheimer's disease (AD). We aimed to investigate its performance in combination with plasma tau levels in patients with non-AD tauopathy. Methods A total of 47 participants were enrolled, including 10 healthy controls, 16 with tauopathy parkin
Like
Comment
Share
